A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

NCT06673654 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

476

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Ruxolitinib Topical Cream 1.5%
DRUG: OPZELURA (Ruxolitinib) Cream
DRUG: Placebo

Sponsor

Sun Pharmaceutical Industries, Inc.